| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | EVP & Chief Financial Officer
3 companies
Mark G Foletta is Director at DXCM, with reported holdings spanning 3 companies. Mark G Foletta's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $6.0M at current prices.
Our model assigns Mark G Foletta a strong insider score of 70/100, based on 15 past trades. Over a 12-month horizon, 75.0% of those trades were profitable, with an average 12-month return of +13.4%.
Mark G Foletta's largest disclosed position is in DXCM as Director, worth about $4.1M. The DXCM filings lean toward selling, a net 35,750 shares.
Mark G Foletta has 69 Form 4 filings on record from April 2015 to July 2026, across 4 companies: Director at DexCom (DXCM), 2018–2026; Director at AMN Healthcare Services (AMN), 2015–2026; Director at Enanta Pharmaceuticals (ENTA), 2020–2026, and 1 more.
The 164 reported transactions were 101 open-market sales, 22 option or other derivative awards, 11 option exercises and 9 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 3 purchases worth about $100K and 28 sales worth about $6.9M.
The largest open-market purchase was 5,000 shares of FBRX at an average $10.00 on April 19, 2017, about $50K.
The largest open-market sale was 6,000 shares of DXCM at an average $117.00 on June 18, 2024, about $702K. Twelve months later DXCM was down 31%.
7 of the 9 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 2 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | DXCM Dexcom, Inc. | Director | Sell10b5-1 | 4,000 | $82.66 | $330,640.00 | -7.6% | - | - | |
| Jun 15, 2026 | DXCM Dexcom, Inc. | Director | Sell10b5-1 | 4,000 | $74.13 | $296,539.60 | -7.0% | +14.1% | - | |
| Jun 15, 2026 | AMN Amn Healthcare Services, Inc. | Director | Sell10b5-1 | 3,681 | $31.07 | $114,361.63 | -17.0% | +10.7% | - | |
| Aug 15, 2025 | DXCM Dexcom Inc | Director | Sell10b5-1 | 2,750 | $81.06 | $222,902.82 | -5.1% | -26.2% | +10.9% | |
| Jul 15, 2025 | DXCM Dexcom Inc | Director | Sell10b5-1 | 2,750 | $85.17 | $234,216.70 | -4.9% | -23.1% | -14.2% | |
| Jun 16, 2025 | DXCM Dexcom Inc | Director | Sell10b5-1 | 2,750 | $83.13 | $228,604.75 | -4.6% | -8.9% | -11.9% | |
| Jun 18, 2024 | DXCM Dexcom Inc | Director | Sell10b5-1 | 6,000 | $117.00 | $702,028.84 | -9.6% | -39.9% | -30.5% | |
| Feb 29, 2024 | AMN Amn Healthcare Services Inc | Director | Buy | 500 | $56.90 | $28,450.00 | +6.2% | -4.0% | -55.0% | |
| Apr 21, 2023 | AMN Amn Healthcare Services Inc | Director | Sale+OE | 1,458 | $88.78 | $129,441.24 | -15.3% | +25.8% | -35.9% | |
| Apr 11, 2023 | AMN Amn Healthcare Services Inc | Director | Sell | 6,042 | $84.35 | $509,638.20 | -42.8% | +31.7% | -30.1% |